[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f6t1VMzBoyuetXwVhU-kwyfJYNzMaaE04sBNaA985Cok":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":83,"rows":90},"Korea University Anam Hospital",[4],109,false,31,7,38245,13,49,[14,16,19,22,24,26,29,31],{"name":15,"count":9},"Coronary Artery Disease",{"name":17,"count":18},"Hypertension",5,{"name":20,"count":21},"Colorectal Cancer",4,{"name":23,"count":21},"Diabetes Mellitus, Type 2",{"name":25,"count":21},"Diabetes Mellitus",{"name":27,"count":28},"Colon Adenoma",3,{"name":30,"count":28},"Atrial Fibrillation",{"name":32,"count":28},"Gastric Cancer",[34,39,44,49,54,58,63,68,73,78],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05990543","Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer","2025-12-01","Nelmastobart and Capecitabine",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06782139","Effects of Enavogliflozin on Coronary Microvascular and Cardiac Function in Obesity","2025-12-31","Enavogliflozin",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT06817616","Arthroscopic Rotator Cuff Repair with UC-MSCs for Large to Massive Tears","2026-04","Injection allogenic Umbilical Cord-derived Mesenchymal Stem Cell",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT06237205","Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination Deficiency","2026-06-30","Niraparib",{"nctId":55,"briefTitle":56,"date":52,"intervention":57},"NCT06187311","Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation","Rivaroxaban 20 MG",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT05427786","A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT ReductioN of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease","2026-07","Nicorandil",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT06293417","To Assess With Ezefeno Tab. in Patients With Dyslipidemia and T2DM","2027-02-01","Ezetimibe\u002Ffenofibrate (Ezefeno) and moderate-intensity statin",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT07510932","Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard Chemotherapies in South Korea Patients (FIRST-K)","2027-03-01","Fruquintinib",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT06767345","Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization","2028-01-25","statins, ezetimibe",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT06767774","Comparison of Pitavastatin Plus Ezetimibe Versus High-Intensity Statin Therapy on Risk of New-Onset Diabetes Mellitus","2029-08-31","Combination therapy",[84,85,86,87,88,89],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[91,128,147,170,191,214,232,250,272,294,317,338,361,379,432,457,482,507,525,552,570,596,614,638,656,680,698,726,744,762,780,808,826,854,872,890,908,933,951,979,997,1024,1042,1067,1085,1112,1130,1154,1179,1205,1229,1266,1290,1308,1332,1356,1374,1400,1418,1443,1461,1479,1504,1528,1555,1573,1591,1620,1638,1663,1681,1705,1731,1749,1774,1792,1841,1869,1894,1922,1945,1971,1997,2023,2049,2067,2092,2116,2134,2162,2180],{"intervention":82,"totalTrials":92,"cells":93},2,{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":99,"PHASE3":101,"PHASE4":103,"NA":126},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[],{"trials":100,"activeCount":96},[],{"trials":102,"activeCount":96},[],{"trials":104,"activeCount":92,"soonestReadout":76},[105,117],{"nctId":79,"briefTitle":80,"status":106,"phases":107,"primaryCompletion":81,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":115},"RECRUITING",[88],"2030-01-31","2025-04-25",2000,[112,113,114],"ASCVD","Diabetes","Statin",[82,116],"High intensity statin monotherapy",{"nctId":74,"briefTitle":75,"status":106,"phases":118,"primaryCompletion":76,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":125},[88],"2028-06-25","2025-05-12",408,[15,123,124],"Atherosclerosis of Coronary Artery","Plaque, Atherosclerotic",[77,82],{"trials":127,"activeCount":96},[],{"intervention":116,"totalTrials":129,"cells":130},1,{"EARLY_PHASE1":131,"PHASE1":133,"PHASE2":135,"PHASE3":137,"PHASE4":139,"NA":145},{"trials":132,"activeCount":96},[],{"trials":134,"activeCount":96},[],{"trials":136,"activeCount":96},[],{"trials":138,"activeCount":96},[],{"trials":140,"activeCount":129,"soonestReadout":81},[141],{"nctId":79,"briefTitle":80,"status":106,"phases":142,"primaryCompletion":81,"completion":108,"start":109,"enrollment":110,"conditions":143,"interventions":144},[88],[112,113,114],[82,116],{"trials":146,"activeCount":96},[],{"intervention":62,"totalTrials":129,"cells":148},{"EARLY_PHASE1":149,"PHASE1":151,"PHASE2":153,"PHASE3":155,"PHASE4":157,"NA":168},{"trials":150,"activeCount":96},[],{"trials":152,"activeCount":96},[],{"trials":154,"activeCount":96},[],{"trials":156,"activeCount":96},[],{"trials":158,"activeCount":129,"soonestReadout":61},[159],{"nctId":59,"briefTitle":60,"status":106,"phases":160,"primaryCompletion":61,"completion":161,"start":162,"enrollment":163,"conditions":164,"interventions":167},[88],"2026-12","2022-12-14",460,[165,15,166],"No-Reflow Phenomenon","Percutaneous Coronary Intervention",[62],{"trials":169,"activeCount":96},[],{"intervention":43,"totalTrials":129,"cells":171},{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":189},{"trials":173,"activeCount":96},[],{"trials":175,"activeCount":96},[],{"trials":177,"activeCount":96},[],{"trials":179,"activeCount":96},[],{"trials":181,"activeCount":129,"soonestReadout":42},[182],{"nctId":40,"briefTitle":41,"status":106,"phases":183,"primaryCompletion":42,"completion":42,"start":184,"enrollment":185,"conditions":186,"interventions":188},[88],"2025-01-20",30,[187],"Obesity and Type 2 Diabetes",[43],{"trials":190,"activeCount":96},[],{"intervention":57,"totalTrials":129,"cells":192},{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":199,"PHASE4":201,"NA":212},{"trials":194,"activeCount":96},[],{"trials":196,"activeCount":96},[],{"trials":198,"activeCount":96},[],{"trials":200,"activeCount":96},[],{"trials":202,"activeCount":129,"soonestReadout":52},[203],{"nctId":55,"briefTitle":56,"status":106,"phases":204,"primaryCompletion":52,"completion":205,"start":206,"enrollment":207,"conditions":208,"interventions":210},[88],"2027-06-30","2023-01-12",940,[30,209],"Anticoagulant Adverse Reaction",[57,211],"Rivaroxaban 15 MG",{"trials":213,"activeCount":96},[],{"intervention":211,"totalTrials":129,"cells":215},{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":230},{"trials":217,"activeCount":96},[],{"trials":219,"activeCount":96},[],{"trials":221,"activeCount":96},[],{"trials":223,"activeCount":96},[],{"trials":225,"activeCount":129,"soonestReadout":52},[226],{"nctId":55,"briefTitle":56,"status":106,"phases":227,"primaryCompletion":52,"completion":205,"start":206,"enrollment":207,"conditions":228,"interventions":229},[88],[30,209],[57,211],{"trials":231,"activeCount":96},[],{"intervention":77,"totalTrials":129,"cells":233},{"EARLY_PHASE1":234,"PHASE1":236,"PHASE2":238,"PHASE3":240,"PHASE4":242,"NA":248},{"trials":235,"activeCount":96},[],{"trials":237,"activeCount":96},[],{"trials":239,"activeCount":96},[],{"trials":241,"activeCount":96},[],{"trials":243,"activeCount":129,"soonestReadout":76},[244],{"nctId":74,"briefTitle":75,"status":106,"phases":245,"primaryCompletion":76,"completion":119,"start":120,"enrollment":121,"conditions":246,"interventions":247},[88],[15,123,124],[77,82],{"trials":249,"activeCount":96},[],{"intervention":53,"totalTrials":129,"cells":251},{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":266,"PHASE4":268,"NA":270},{"trials":253,"activeCount":96},[],{"trials":255,"activeCount":96},[],{"trials":257,"activeCount":129,"soonestReadout":52},[258],{"nctId":50,"briefTitle":51,"status":259,"phases":260,"primaryCompletion":52,"completion":205,"start":261,"enrollment":262,"conditions":263,"interventions":265},"NOT_YET_RECRUITING",[86],"2024-02-27",33,[264],"Efficacy",[53],{"trials":267,"activeCount":96},[],{"trials":269,"activeCount":96},[],{"trials":271,"activeCount":96},[],{"intervention":72,"totalTrials":129,"cells":273},{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":278,"PHASE3":288,"PHASE4":290,"NA":292},{"trials":275,"activeCount":96},[],{"trials":277,"activeCount":96},[],{"trials":279,"activeCount":129,"soonestReadout":71},[280],{"nctId":69,"briefTitle":70,"status":259,"phases":281,"primaryCompletion":71,"completion":282,"start":283,"enrollment":284,"conditions":285,"interventions":287},[86],"2027-09-01","2026-05-01",88,[286],"Colon Cancer",[72],{"trials":289,"activeCount":96},[],{"trials":291,"activeCount":96},[],{"trials":293,"activeCount":96},[],{"intervention":38,"totalTrials":129,"cells":295},{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":300,"PHASE3":311,"PHASE4":313,"NA":315},{"trials":297,"activeCount":96},[],{"trials":299,"activeCount":96},[],{"trials":301,"activeCount":129,"soonestReadout":37},[302],{"nctId":35,"briefTitle":36,"status":303,"phases":304,"primaryCompletion":37,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":310},"ACTIVE_NOT_RECRUITING",[85,86],"2026-12-31","2024-01-29",59,[309],"Recurrent or Metastatic Colorectal Cancer",[38],{"trials":312,"activeCount":96},[],{"trials":314,"activeCount":96},[],{"trials":316,"activeCount":96},[],{"intervention":48,"totalTrials":129,"cells":318},{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":325,"PHASE4":327,"NA":329},{"trials":320,"activeCount":96},[],{"trials":322,"activeCount":96},[],{"trials":324,"activeCount":96},[],{"trials":326,"activeCount":96},[],{"trials":328,"activeCount":96},[],{"trials":330,"activeCount":129,"soonestReadout":47},[331],{"nctId":45,"briefTitle":46,"status":106,"phases":332,"primaryCompletion":47,"completion":47,"start":333,"enrollment":334,"conditions":335,"interventions":337},[89],"2025-01-17",15,[336],"Rotator Cuff Disease",[48],{"intervention":67,"totalTrials":129,"cells":339},{"EARLY_PHASE1":340,"PHASE1":342,"PHASE2":344,"PHASE3":346,"PHASE4":348,"NA":350},{"trials":341,"activeCount":96},[],{"trials":343,"activeCount":96},[],{"trials":345,"activeCount":96},[],{"trials":347,"activeCount":96},[],{"trials":349,"activeCount":96},[],{"trials":351,"activeCount":129,"soonestReadout":66},[352],{"nctId":64,"briefTitle":65,"status":106,"phases":353,"primaryCompletion":66,"completion":66,"start":354,"enrollment":355,"conditions":356,"interventions":359},[89],"2024-03-01",3958,[357,358],"T2DM (Type 2 Diabetes Mellitus)","Dyslipidemias",[67,360],"Dose escalation of moderate-intensity statin",{"intervention":360,"totalTrials":129,"cells":362},{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":371,"NA":373},{"trials":364,"activeCount":96},[],{"trials":366,"activeCount":96},[],{"trials":368,"activeCount":96},[],{"trials":370,"activeCount":96},[],{"trials":372,"activeCount":96},[],{"trials":374,"activeCount":129,"soonestReadout":66},[375],{"nctId":64,"briefTitle":65,"status":106,"phases":376,"primaryCompletion":66,"completion":66,"start":354,"enrollment":355,"conditions":377,"interventions":378},[89],[357,358],[67,360],{"intervention":380,"totalTrials":28,"cells":381},"Pioglitazone",{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":390,"NA":430},{"trials":383,"activeCount":96},[],{"trials":385,"activeCount":96},[],{"trials":387,"activeCount":96},[],{"trials":389,"activeCount":96},[],{"trials":391,"activeCount":96},[392,404,418],{"nctId":393,"briefTitle":394,"status":395,"phases":396,"primaryCompletion":397,"completion":398,"start":399,"enrollment":400,"conditions":401,"interventions":403},"NCT00494559","The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers","COMPLETED",[88],"2008-07","2015-07","2007-07",240,[25,402],"Coronary Artery Stenosis",[380],{"nctId":405,"briefTitle":406,"status":407,"phases":408,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":413,"interventions":415},"NCT01339143","Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes","UNKNOWN",[88],"2012-12","2013-05","2010-04",80,[25,414],"Oxidative Stress",[416,417],"Galvus","pioglitazone",{"nctId":419,"briefTitle":420,"status":395,"phases":421,"primaryCompletion":422,"completion":423,"start":424,"enrollment":425,"conditions":426,"interventions":429},"NCT01331967","The Effect of Pioglitazone on Neointima Volume and Characteristics Observed by Optical Coherence Tomography (OCT)",[88],"2013-02","2013-08","2011-02",94,[427,428],"Diabetic Stable Angina","Diabetic Unstable Angina",[380],{"trials":431,"activeCount":96},[],{"intervention":433,"totalTrials":129,"cells":434},"Rubus occidentalis extract",{"EARLY_PHASE1":435,"PHASE1":437,"PHASE2":439,"PHASE3":441,"PHASE4":443,"NA":455},{"trials":436,"activeCount":96},[],{"trials":438,"activeCount":96},[],{"trials":440,"activeCount":96},[],{"trials":442,"activeCount":96},[],{"trials":444,"activeCount":96},[445],{"nctId":446,"briefTitle":447,"status":395,"phases":448,"primaryCompletion":449,"start":450,"enrollment":451,"conditions":452,"interventions":454},"NCT01964703","Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes",[88],"2013-10","2013-04",29,[453],"Prediabetes (Impaired Fasting Glucose and\u002For Impaired Glucose Tolerance)",[433],{"trials":456,"activeCount":96},[],{"intervention":458,"totalTrials":129,"cells":459},"cilostazol",{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":466,"PHASE4":468,"NA":480},{"trials":461,"activeCount":96},[],{"trials":463,"activeCount":96},[],{"trials":465,"activeCount":96},[],{"trials":467,"activeCount":96},[],{"trials":469,"activeCount":96},[470],{"nctId":471,"briefTitle":472,"status":407,"phases":473,"completion":474,"start":475,"enrollment":476,"conditions":477,"interventions":479},"NCT00573950","Effects of Cilostazol on Plasma Adipocytokine and Arterial Stiffness",[88],"2008-12","2007-12",48,[23,478],"Metabolic Syndrome X",[458],{"trials":481,"activeCount":96},[],{"intervention":483,"totalTrials":129,"cells":484},"3% diquafosol",{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":505},{"trials":486,"activeCount":96},[],{"trials":488,"activeCount":96},[],{"trials":490,"activeCount":96},[],{"trials":492,"activeCount":96},[],{"trials":494,"activeCount":96},[495],{"nctId":496,"briefTitle":497,"status":395,"phases":498,"primaryCompletion":499,"completion":499,"start":500,"enrollment":185,"conditions":501,"interventions":503},"NCT07297316","Immediate Therapeutic Effects of Diquafosol and Rebamipide in Dry Eye Disease",[88],"2024-08-30","2022-10-03",[502],"Dry Eye Disease (DED)",[483,504],"2% rebamipide",{"trials":506,"activeCount":96},[],{"intervention":504,"totalTrials":129,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":523},{"trials":510,"activeCount":96},[],{"trials":512,"activeCount":96},[],{"trials":514,"activeCount":96},[],{"trials":516,"activeCount":96},[],{"trials":518,"activeCount":96},[519],{"nctId":496,"briefTitle":497,"status":395,"phases":520,"primaryCompletion":499,"completion":499,"start":500,"enrollment":185,"conditions":521,"interventions":522},[88],[502],[483,504],{"trials":524,"activeCount":96},[],{"intervention":526,"totalTrials":129,"cells":527},"combination of high-dose rosuvastatin and ezetimibe",{"EARLY_PHASE1":528,"PHASE1":530,"PHASE2":532,"PHASE3":534,"PHASE4":536,"NA":550},{"trials":529,"activeCount":96},[],{"trials":531,"activeCount":96},[],{"trials":533,"activeCount":96},[],{"trials":535,"activeCount":96},[],{"trials":537,"activeCount":96},[538],{"nctId":539,"briefTitle":540,"status":407,"phases":541,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":546,"interventions":548},"NCT05884502","A Multicenter Study to Evaluate the Effect of High Dose Rosuvastatin Versus Rosuvastatin and Ezetimibe in Stroke",[88],"2023-12-31","2024-12-31","2022-09-01",330,[358,547],"Stroke, Acute Ischemic",[526,549],"high-dose rosuvastatin single administration",{"trials":551,"activeCount":96},[],{"intervention":549,"totalTrials":129,"cells":553},{"EARLY_PHASE1":554,"PHASE1":556,"PHASE2":558,"PHASE3":560,"PHASE4":562,"NA":568},{"trials":555,"activeCount":96},[],{"trials":557,"activeCount":96},[],{"trials":559,"activeCount":96},[],{"trials":561,"activeCount":96},[],{"trials":563,"activeCount":96},[564],{"nctId":539,"briefTitle":540,"status":407,"phases":565,"primaryCompletion":542,"completion":543,"start":544,"enrollment":545,"conditions":566,"interventions":567},[88],[358,547],[526,549],{"trials":569,"activeCount":96},[],{"intervention":571,"totalTrials":129,"cells":572},"Sugammadex",{"EARLY_PHASE1":573,"PHASE1":575,"PHASE2":577,"PHASE3":579,"PHASE4":581,"NA":594},{"trials":574,"activeCount":96},[],{"trials":576,"activeCount":96},[],{"trials":578,"activeCount":96},[],{"trials":580,"activeCount":96},[],{"trials":582,"activeCount":96},[583],{"nctId":584,"briefTitle":585,"status":407,"phases":586,"primaryCompletion":587,"completion":588,"start":589,"enrollment":412,"conditions":590,"interventions":592},"NCT02329964","Effectiveness of Sugammadex in LMS Surgery",[88],"2015-08","2016-09","2015-02",[591],"Muscle Relaxation",[571,593],"Neostigmine",{"trials":595,"activeCount":96},[],{"intervention":593,"totalTrials":129,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":606,"NA":612},{"trials":599,"activeCount":96},[],{"trials":601,"activeCount":96},[],{"trials":603,"activeCount":96},[],{"trials":605,"activeCount":96},[],{"trials":607,"activeCount":96},[608],{"nctId":584,"briefTitle":585,"status":407,"phases":609,"primaryCompletion":587,"completion":588,"start":589,"enrollment":412,"conditions":610,"interventions":611},[88],[591],[571,593],{"trials":613,"activeCount":96},[],{"intervention":615,"totalTrials":129,"cells":616},"telmisartan",{"EARLY_PHASE1":617,"PHASE1":619,"PHASE2":621,"PHASE3":623,"PHASE4":625,"NA":636},{"trials":618,"activeCount":96},[],{"trials":620,"activeCount":96},[],{"trials":622,"activeCount":96},[],{"trials":624,"activeCount":96},[],{"trials":626,"activeCount":96},[627],{"nctId":628,"briefTitle":629,"status":395,"phases":630,"primaryCompletion":397,"start":631,"enrollment":632,"conditions":633,"interventions":634},"NCT00599885","Comparison of Effects of Telmisartan and Valsartan on Neointima Volume in Diabetes",[88],"2007-09",72,[17,113,15],[615,635],"valsartan",{"trials":637,"activeCount":96},[],{"intervention":635,"totalTrials":129,"cells":639},{"EARLY_PHASE1":640,"PHASE1":642,"PHASE2":644,"PHASE3":646,"PHASE4":648,"NA":654},{"trials":641,"activeCount":96},[],{"trials":643,"activeCount":96},[],{"trials":645,"activeCount":96},[],{"trials":647,"activeCount":96},[],{"trials":649,"activeCount":96},[650],{"nctId":628,"briefTitle":629,"status":395,"phases":651,"primaryCompletion":397,"start":631,"enrollment":632,"conditions":652,"interventions":653},[88],[17,113,15],[615,635],{"trials":655,"activeCount":96},[],{"intervention":657,"totalTrials":129,"cells":658},"Fluorometholone 0.1% ophthalmic solution",{"EARLY_PHASE1":659,"PHASE1":661,"PHASE2":663,"PHASE3":665,"PHASE4":667,"NA":678},{"trials":660,"activeCount":96},[],{"trials":662,"activeCount":96},[],{"trials":664,"activeCount":96},[],{"trials":666,"activeCount":96},[],{"trials":668,"activeCount":96},[669],{"nctId":670,"briefTitle":671,"status":395,"phases":672,"primaryCompletion":354,"completion":673,"start":544,"enrollment":674,"conditions":675,"interventions":676},"NCT06876116","Once-daily Fluorometholone vs Twice-daily Cyclosporine in Dry Eye Disease",[88],"2024-05-24",32,[502],[657,677],"Cyclosporine 0.05% eye drops",{"trials":679,"activeCount":96},[],{"intervention":677,"totalTrials":129,"cells":681},{"EARLY_PHASE1":682,"PHASE1":684,"PHASE2":686,"PHASE3":688,"PHASE4":690,"NA":696},{"trials":683,"activeCount":96},[],{"trials":685,"activeCount":96},[],{"trials":687,"activeCount":96},[],{"trials":689,"activeCount":96},[],{"trials":691,"activeCount":96},[692],{"nctId":670,"briefTitle":671,"status":395,"phases":693,"primaryCompletion":354,"completion":673,"start":544,"enrollment":674,"conditions":694,"interventions":695},[88],[502],[657,677],{"trials":697,"activeCount":96},[],{"intervention":699,"totalTrials":129,"cells":700},"Dexmedetomidine",{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":707,"PHASE4":709,"NA":724},{"trials":702,"activeCount":96},[],{"trials":704,"activeCount":96},[],{"trials":706,"activeCount":96},[],{"trials":708,"activeCount":96},[],{"trials":710,"activeCount":96},[711],{"nctId":712,"briefTitle":713,"status":407,"phases":714,"primaryCompletion":715,"completion":588,"start":587,"enrollment":716,"conditions":717,"interventions":719},"NCT02464722","Comparision Between Hemodynamic Response of Dexmedetomidine and Remifentanil on Anesthesia in Endoscopic Sinus Surgery",[88],"2015-11",50,[718],"Hemodynamic Instability",[699,720,721,722,723],"Remifentanil","Epinephrine","Propofol","Rocuronium",{"trials":725,"activeCount":96},[],{"intervention":720,"totalTrials":129,"cells":727},{"EARLY_PHASE1":728,"PHASE1":730,"PHASE2":732,"PHASE3":734,"PHASE4":736,"NA":742},{"trials":729,"activeCount":96},[],{"trials":731,"activeCount":96},[],{"trials":733,"activeCount":96},[],{"trials":735,"activeCount":96},[],{"trials":737,"activeCount":96},[738],{"nctId":712,"briefTitle":713,"status":407,"phases":739,"primaryCompletion":715,"completion":588,"start":587,"enrollment":716,"conditions":740,"interventions":741},[88],[718],[699,720,721,722,723],{"trials":743,"activeCount":96},[],{"intervention":721,"totalTrials":129,"cells":745},{"EARLY_PHASE1":746,"PHASE1":748,"PHASE2":750,"PHASE3":752,"PHASE4":754,"NA":760},{"trials":747,"activeCount":96},[],{"trials":749,"activeCount":96},[],{"trials":751,"activeCount":96},[],{"trials":753,"activeCount":96},[],{"trials":755,"activeCount":96},[756],{"nctId":712,"briefTitle":713,"status":407,"phases":757,"primaryCompletion":715,"completion":588,"start":587,"enrollment":716,"conditions":758,"interventions":759},[88],[718],[699,720,721,722,723],{"trials":761,"activeCount":96},[],{"intervention":723,"totalTrials":129,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":770,"PHASE4":772,"NA":778},{"trials":765,"activeCount":96},[],{"trials":767,"activeCount":96},[],{"trials":769,"activeCount":96},[],{"trials":771,"activeCount":96},[],{"trials":773,"activeCount":96},[774],{"nctId":712,"briefTitle":713,"status":407,"phases":775,"primaryCompletion":715,"completion":588,"start":587,"enrollment":716,"conditions":776,"interventions":777},[88],[718],[699,720,721,722,723],{"trials":779,"activeCount":96},[],{"intervention":781,"totalTrials":129,"cells":782},"Rosuvastatin 5mg",{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":787,"PHASE3":789,"PHASE4":791,"NA":806},{"trials":784,"activeCount":96},[],{"trials":786,"activeCount":96},[],{"trials":788,"activeCount":96},[],{"trials":790,"activeCount":96},[],{"trials":792,"activeCount":96},[793],{"nctId":794,"briefTitle":795,"status":407,"phases":796,"primaryCompletion":797,"completion":798,"start":799,"enrollment":800,"conditions":801,"interventions":804},"NCT02859480","Dose-dependent Effect of Rosuvastatin on Long-term Clinical Outcomes After PCI",[88],"2019-06","2019-12","2015-09",300,[15,802,803],"Coronary Disease","Cardiovascular Diseases",[781,805],"Rosuvastatin 20mg",{"trials":807,"activeCount":96},[],{"intervention":805,"totalTrials":129,"cells":809},{"EARLY_PHASE1":810,"PHASE1":812,"PHASE2":814,"PHASE3":816,"PHASE4":818,"NA":824},{"trials":811,"activeCount":96},[],{"trials":813,"activeCount":96},[],{"trials":815,"activeCount":96},[],{"trials":817,"activeCount":96},[],{"trials":819,"activeCount":96},[820],{"nctId":794,"briefTitle":795,"status":407,"phases":821,"primaryCompletion":797,"completion":798,"start":799,"enrollment":800,"conditions":822,"interventions":823},[88],[15,802,803],[781,805],{"trials":825,"activeCount":96},[],{"intervention":827,"totalTrials":129,"cells":828},"Rocuronium bromide 0.15 mg kg-1",{"EARLY_PHASE1":829,"PHASE1":831,"PHASE2":833,"PHASE3":835,"PHASE4":837,"NA":852},{"trials":830,"activeCount":96},[],{"trials":832,"activeCount":96},[],{"trials":834,"activeCount":96},[],{"trials":836,"activeCount":96},[],{"trials":838,"activeCount":96},[839],{"nctId":840,"briefTitle":841,"status":407,"phases":842,"primaryCompletion":843,"completion":844,"start":398,"enrollment":845,"conditions":846,"interventions":848},"NCT02467595","The Effect of no Muscle Relaxant Versus Reduced-dose Rocuronium on Anesthesia in Adenotonsillectomy",[88],"2016-10","2016-12",75,[847],"Muscle Relaxants",[827,849,850,722,851],"Rocuronium bromide 0.3 mg kg-1","Fentanyl","Sevoflurane",{"trials":853,"activeCount":96},[],{"intervention":849,"totalTrials":129,"cells":855},{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":862,"PHASE4":864,"NA":870},{"trials":857,"activeCount":96},[],{"trials":859,"activeCount":96},[],{"trials":861,"activeCount":96},[],{"trials":863,"activeCount":96},[],{"trials":865,"activeCount":96},[866],{"nctId":840,"briefTitle":841,"status":407,"phases":867,"primaryCompletion":843,"completion":844,"start":398,"enrollment":845,"conditions":868,"interventions":869},[88],[847],[827,849,850,722,851],{"trials":871,"activeCount":96},[],{"intervention":850,"totalTrials":129,"cells":873},{"EARLY_PHASE1":874,"PHASE1":876,"PHASE2":878,"PHASE3":880,"PHASE4":882,"NA":888},{"trials":875,"activeCount":96},[],{"trials":877,"activeCount":96},[],{"trials":879,"activeCount":96},[],{"trials":881,"activeCount":96},[],{"trials":883,"activeCount":96},[884],{"nctId":840,"briefTitle":841,"status":407,"phases":885,"primaryCompletion":843,"completion":844,"start":398,"enrollment":845,"conditions":886,"interventions":887},[88],[847],[827,849,850,722,851],{"trials":889,"activeCount":96},[],{"intervention":851,"totalTrials":129,"cells":891},{"EARLY_PHASE1":892,"PHASE1":894,"PHASE2":896,"PHASE3":898,"PHASE4":900,"NA":906},{"trials":893,"activeCount":96},[],{"trials":895,"activeCount":96},[],{"trials":897,"activeCount":96},[],{"trials":899,"activeCount":96},[],{"trials":901,"activeCount":96},[902],{"nctId":840,"briefTitle":841,"status":407,"phases":903,"primaryCompletion":843,"completion":844,"start":398,"enrollment":845,"conditions":904,"interventions":905},[88],[847],[827,849,850,722,851],{"trials":907,"activeCount":96},[],{"intervention":909,"totalTrials":129,"cells":910},"L-carnitine",{"EARLY_PHASE1":911,"PHASE1":913,"PHASE2":915,"PHASE3":917,"PHASE4":919,"NA":931},{"trials":912,"activeCount":96},[],{"trials":914,"activeCount":96},[],{"trials":916,"activeCount":96},[],{"trials":918,"activeCount":96},[],{"trials":920,"activeCount":96},[921],{"nctId":922,"briefTitle":923,"status":395,"phases":924,"primaryCompletion":925,"completion":925,"start":926,"enrollment":927,"conditions":928,"interventions":930},"NCT01769157","Effects of L-carnitine on Hypothyroidism",[88],"2013-06","2012-08",60,[929],"Hypothyroidism",[909],{"trials":932,"activeCount":96},[],{"intervention":416,"totalTrials":129,"cells":934},{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":941,"PHASE4":943,"NA":949},{"trials":936,"activeCount":96},[],{"trials":938,"activeCount":96},[],{"trials":940,"activeCount":96},[],{"trials":942,"activeCount":96},[],{"trials":944,"activeCount":96},[945],{"nctId":405,"briefTitle":406,"status":407,"phases":946,"primaryCompletion":409,"completion":410,"start":411,"enrollment":412,"conditions":947,"interventions":948},[88],[25,414],[416,417],{"trials":950,"activeCount":96},[],{"intervention":952,"totalTrials":129,"cells":953},"Pitavastatin 1mg",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":960,"PHASE4":962,"NA":977},{"trials":955,"activeCount":96},[],{"trials":957,"activeCount":96},[],{"trials":959,"activeCount":96},[],{"trials":961,"activeCount":96},[],{"trials":963,"activeCount":96},[964],{"nctId":965,"briefTitle":966,"status":395,"phases":967,"primaryCompletion":968,"completion":969,"start":422,"enrollment":970,"conditions":971,"interventions":975},"NCT02545231","Effect of Low-dose vs. High-dose Pitavastatin on In-stent Restenosis",[88],"2018-12","2020-08",1000,[972,973,974],"Atherosclerosis","Neointima","Angina",[952,976],"Pitavastatin 4mg",{"trials":978,"activeCount":96},[],{"intervention":976,"totalTrials":129,"cells":980},{"EARLY_PHASE1":981,"PHASE1":983,"PHASE2":985,"PHASE3":987,"PHASE4":989,"NA":995},{"trials":982,"activeCount":96},[],{"trials":984,"activeCount":96},[],{"trials":986,"activeCount":96},[],{"trials":988,"activeCount":96},[],{"trials":990,"activeCount":96},[991],{"nctId":965,"briefTitle":966,"status":395,"phases":992,"primaryCompletion":968,"completion":969,"start":422,"enrollment":970,"conditions":993,"interventions":994},[88],[972,973,974],[952,976],{"trials":996,"activeCount":96},[],{"intervention":998,"totalTrials":129,"cells":999},"Rosuvastatin and Ezetimibe",{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1006,"PHASE4":1008,"NA":1022},{"trials":1001,"activeCount":96},[],{"trials":1003,"activeCount":96},[],{"trials":1005,"activeCount":96},[],{"trials":1007,"activeCount":96},[],{"trials":1009,"activeCount":96},[1010],{"nctId":1011,"briefTitle":1012,"status":395,"phases":1013,"primaryCompletion":1014,"completion":1015,"start":1016,"enrollment":1017,"conditions":1018,"interventions":1020},"NCT04826354","Effects of Statin for Elderly Patients With Atherosclerotic Cardiovascular Disease",[88],"2023-05-14","2023-06-28","2021-08-11",582,[1019],"Atheroscleroses, Coronary",[998,1021],"Rosuvastatin",{"trials":1023,"activeCount":96},[],{"intervention":1021,"totalTrials":129,"cells":1025},{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1032,"PHASE4":1034,"NA":1040},{"trials":1027,"activeCount":96},[],{"trials":1029,"activeCount":96},[],{"trials":1031,"activeCount":96},[],{"trials":1033,"activeCount":96},[],{"trials":1035,"activeCount":96},[1036],{"nctId":1011,"briefTitle":1012,"status":395,"phases":1037,"primaryCompletion":1014,"completion":1015,"start":1016,"enrollment":1017,"conditions":1038,"interventions":1039},[88],[1019],[998,1021],{"trials":1041,"activeCount":96},[],{"intervention":1043,"totalTrials":129,"cells":1044},"Ticagrelor",{"EARLY_PHASE1":1045,"PHASE1":1047,"PHASE2":1049,"PHASE3":1051,"PHASE4":1053,"NA":1065},{"trials":1046,"activeCount":96},[],{"trials":1048,"activeCount":96},[],{"trials":1050,"activeCount":96},[],{"trials":1052,"activeCount":96},[],{"trials":1054,"activeCount":96},[1055],{"nctId":1056,"briefTitle":1057,"status":395,"phases":1058,"primaryCompletion":1059,"completion":1060,"start":398,"enrollment":927,"conditions":1061,"interventions":1063},"NCT02487732","Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting",[88],"2016-08","2017-01",[1062],"Acute Coronary Syndrome",[1043,1064],"Prasugrel",{"trials":1066,"activeCount":96},[],{"intervention":1064,"totalTrials":129,"cells":1068},{"EARLY_PHASE1":1069,"PHASE1":1071,"PHASE2":1073,"PHASE3":1075,"PHASE4":1077,"NA":1083},{"trials":1070,"activeCount":96},[],{"trials":1072,"activeCount":96},[],{"trials":1074,"activeCount":96},[],{"trials":1076,"activeCount":96},[],{"trials":1078,"activeCount":96},[1079],{"nctId":1056,"briefTitle":1057,"status":395,"phases":1080,"primaryCompletion":1059,"completion":1060,"start":398,"enrollment":927,"conditions":1081,"interventions":1082},[88],[1062],[1043,1064],{"trials":1084,"activeCount":96},[],{"intervention":1086,"totalTrials":129,"cells":1087},"Diltiazem",{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1094,"PHASE4":1096,"NA":1110},{"trials":1089,"activeCount":96},[],{"trials":1091,"activeCount":96},[],{"trials":1093,"activeCount":96},[],{"trials":1095,"activeCount":96},[],{"trials":1097,"activeCount":96},[1098],{"nctId":1099,"briefTitle":1100,"status":395,"phases":1101,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":1105,"interventions":1107},"NCT03930433","The Effect of Nebivolol in Hypertensive Patients With Coronary Arterial Spasm",[88],"2019-03-31","2018-01-01",51,[1106],"Coronary Vasospasm",[1108,1086,1109],"Nebivolol","Nebivolol+Diltiazem",{"trials":1111,"activeCount":96},[],{"intervention":1109,"totalTrials":129,"cells":1113},{"EARLY_PHASE1":1114,"PHASE1":1116,"PHASE2":1118,"PHASE3":1120,"PHASE4":1122,"NA":1128},{"trials":1115,"activeCount":96},[],{"trials":1117,"activeCount":96},[],{"trials":1119,"activeCount":96},[],{"trials":1121,"activeCount":96},[],{"trials":1123,"activeCount":96},[1124],{"nctId":1099,"briefTitle":1100,"status":395,"phases":1125,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":1126,"interventions":1127},[88],[1106],[1108,1086,1109],{"trials":1129,"activeCount":96},[],{"intervention":1131,"totalTrials":129,"cells":1132},"Evolocumab",{"EARLY_PHASE1":1133,"PHASE1":1135,"PHASE2":1137,"PHASE3":1139,"PHASE4":1141,"NA":1152},{"trials":1134,"activeCount":96},[],{"trials":1136,"activeCount":96},[],{"trials":1138,"activeCount":96},[],{"trials":1140,"activeCount":96},[],{"trials":1142,"activeCount":96},[1143],{"nctId":1144,"briefTitle":1145,"status":407,"phases":1146,"primaryCompletion":1147,"completion":1147,"start":1148,"enrollment":927,"conditions":1149,"interventions":1151},"NCT04719221","Impact of Evolocumab as an Additional Lipid-lowering Therapy to Changes in Lipid Core Burden Index of Non-culprit Vulnerable Plaque in Patients Who Underwent Percutaneous Coronary Intervention for the Acute Coronary Syndrome",[88],"2024-12","2021-03-01",[1150,1062],"Clinical Trial",[1131],{"trials":1153,"activeCount":96},[],{"intervention":1155,"totalTrials":129,"cells":1156},"Rocuronium bromide",{"EARLY_PHASE1":1157,"PHASE1":1159,"PHASE2":1161,"PHASE3":1163,"PHASE4":1165,"NA":1177},{"trials":1158,"activeCount":96},[],{"trials":1160,"activeCount":96},[],{"trials":1162,"activeCount":96},[],{"trials":1164,"activeCount":96},[],{"trials":1166,"activeCount":96},[1167],{"nctId":1168,"briefTitle":1169,"status":407,"phases":1170,"primaryCompletion":1171,"completion":1172,"start":715,"enrollment":1173,"conditions":1174,"interventions":1176},"NCT02586441","Evaluation of EEG With Respect to the Change of Depth of Anesthesia During General Anesthesia",[88],"2016-11","2017-11",40,[1175],"Anesthesia",[722,1155],{"trials":1178,"activeCount":96},[],{"intervention":1180,"totalTrials":129,"cells":1181},"atorvastatin",{"EARLY_PHASE1":1182,"PHASE1":1184,"PHASE2":1186,"PHASE3":1188,"PHASE4":1190,"NA":1203},{"trials":1183,"activeCount":96},[],{"trials":1185,"activeCount":96},[],{"trials":1187,"activeCount":96},[],{"trials":1189,"activeCount":96},[],{"trials":1191,"activeCount":96},[1192],{"nctId":1193,"briefTitle":1194,"status":395,"phases":1195,"primaryCompletion":1196,"completion":1197,"start":1198,"enrollment":1199,"conditions":1200,"interventions":1202},"NCT00536887","Effects of Atorvastatin 10 mg Versus 40 mg in Eight Months Follow-up Coronary Flow Reserve and Bone Marrow Stem Cell Mobilization in Patients With Acute Myocardial Infarction",[88],"2008-01","2008-09","2005-07",100,[1201],"Acute Myocardial Infarction",[1180],{"trials":1204,"activeCount":96},[],{"intervention":1206,"totalTrials":129,"cells":1207},"Pioglitazone, Rosiglitazone",{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1212,"PHASE3":1214,"PHASE4":1216,"NA":1227},{"trials":1209,"activeCount":96},[],{"trials":1211,"activeCount":96},[],{"trials":1213,"activeCount":96},[],{"trials":1215,"activeCount":96},[],{"trials":1217,"activeCount":96},[1218],{"nctId":1219,"briefTitle":1220,"status":395,"phases":1221,"completion":1222,"start":1223,"enrollment":1173,"conditions":1224,"interventions":1226},"NCT00314561","The Effect of Pioglitazone and Rosiglitazone on Atherosclerotic and Inflammatory Markers in Patients With Metabolic Syndrome",[88],"2006-12","2006-05",[1225],"Metabolic Syndrome",[1206],{"trials":1228,"activeCount":96},[],{"intervention":1230,"totalTrials":92,"cells":1231},"PEG-Asc",{"EARLY_PHASE1":1232,"PHASE1":1234,"PHASE2":1236,"PHASE3":1238,"PHASE4":1262,"NA":1264},{"trials":1233,"activeCount":96},[],{"trials":1235,"activeCount":96},[],{"trials":1237,"activeCount":96},[],{"trials":1239,"activeCount":96},[1240,1251],{"nctId":1241,"briefTitle":1242,"status":395,"phases":1243,"primaryCompletion":1244,"completion":1245,"start":1246,"enrollment":1247,"conditions":1248,"interventions":1249},"NCT02548403","Effect of Simethicone on Bowel Preparation for Colonoscopy",[87],"2014-09","2014-11","2014-07",260,[20],[1230,1250],"PEG-Asc with simethicone",{"nctId":1252,"briefTitle":1253,"status":395,"phases":1254,"primaryCompletion":1255,"completion":1256,"start":1257,"enrollment":1258,"conditions":1259,"interventions":1260},"NCT02250196","A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods",[87],"2013-09","2013-11","2013-03",200,[20,27],[1230,1261],"SPMC 2",{"trials":1263,"activeCount":96},[],{"trials":1265,"activeCount":96},[],{"intervention":1267,"totalTrials":129,"cells":1268},"triple combination therapy",{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1273,"PHASE3":1275,"PHASE4":1286,"NA":1288},{"trials":1270,"activeCount":96},[],{"trials":1272,"activeCount":96},[],{"trials":1274,"activeCount":96},[],{"trials":1276,"activeCount":96},[1277],{"nctId":1278,"briefTitle":1279,"status":407,"phases":1280,"primaryCompletion":798,"completion":798,"start":844,"enrollment":1281,"conditions":1282,"interventions":1284},"NCT02946632","Effectiveness & Tolerability of Novel, Initial Triple Combination Therapy vs Conventional Therapy in Type 2 Diabetes",[87],104,[1283],"Diabetes Mellitus, Type II",[1267,1285],"Stepwise add-on therapy",{"trials":1287,"activeCount":96},[],{"trials":1289,"activeCount":96},[],{"intervention":1285,"totalTrials":129,"cells":1291},{"EARLY_PHASE1":1292,"PHASE1":1294,"PHASE2":1296,"PHASE3":1298,"PHASE4":1304,"NA":1306},{"trials":1293,"activeCount":96},[],{"trials":1295,"activeCount":96},[],{"trials":1297,"activeCount":96},[],{"trials":1299,"activeCount":96},[1300],{"nctId":1278,"briefTitle":1279,"status":407,"phases":1301,"primaryCompletion":798,"completion":798,"start":844,"enrollment":1281,"conditions":1302,"interventions":1303},[87],[1283],[1267,1285],{"trials":1305,"activeCount":96},[],{"trials":1307,"activeCount":96},[],{"intervention":1309,"totalTrials":129,"cells":1310},"Somatostatin",{"EARLY_PHASE1":1311,"PHASE1":1313,"PHASE2":1315,"PHASE3":1317,"PHASE4":1328,"NA":1330},{"trials":1312,"activeCount":96},[],{"trials":1314,"activeCount":96},[],{"trials":1316,"activeCount":96},[],{"trials":1318,"activeCount":96},[1319],{"nctId":1320,"briefTitle":1321,"status":407,"phases":1322,"primaryCompletion":1323,"start":398,"enrollment":1324,"conditions":1325,"interventions":1327},"NCT02882347","The Effect of Somatostatin for Treatment of Post Hepatectomy Liver Failure (PHLF)",[87],"2017-07",20,[1326],"Liver Failure",[1309],{"trials":1329,"activeCount":96},[],{"trials":1331,"activeCount":96},[],{"intervention":1333,"totalTrials":129,"cells":1334},"Polyethylene glycol",{"EARLY_PHASE1":1335,"PHASE1":1337,"PHASE2":1339,"PHASE3":1341,"PHASE4":1352,"NA":1354},{"trials":1336,"activeCount":96},[],{"trials":1338,"activeCount":96},[],{"trials":1340,"activeCount":96},[],{"trials":1342,"activeCount":96},[1343],{"nctId":1344,"briefTitle":1345,"status":395,"phases":1346,"primaryCompletion":1347,"completion":409,"start":1348,"enrollment":1258,"conditions":1349,"interventions":1350},"NCT01778192","A Randomized Prospective Trial Comparing Polyethylene Glycol and Sodium Picosulphate With Magnesium Citrate",[87],"2012-11","2012-07",[20,27],[1333,1333,1351,1351],"Sodium picosulphate with magnesium citrate",{"trials":1353,"activeCount":96},[],{"trials":1355,"activeCount":96},[],{"intervention":1351,"totalTrials":129,"cells":1357},{"EARLY_PHASE1":1358,"PHASE1":1360,"PHASE2":1362,"PHASE3":1364,"PHASE4":1370,"NA":1372},{"trials":1359,"activeCount":96},[],{"trials":1361,"activeCount":96},[],{"trials":1363,"activeCount":96},[],{"trials":1365,"activeCount":96},[1366],{"nctId":1344,"briefTitle":1345,"status":395,"phases":1367,"primaryCompletion":1347,"completion":409,"start":1348,"enrollment":1258,"conditions":1368,"interventions":1369},[87],[20,27],[1333,1333,1351,1351],{"trials":1371,"activeCount":96},[],{"trials":1373,"activeCount":96},[],{"intervention":1375,"totalTrials":129,"cells":1376},"Sugammadex Sodium",{"EARLY_PHASE1":1377,"PHASE1":1379,"PHASE2":1381,"PHASE3":1383,"PHASE4":1396,"NA":1398},{"trials":1378,"activeCount":96},[],{"trials":1380,"activeCount":96},[],{"trials":1382,"activeCount":96},[],{"trials":1384,"activeCount":96},[1385],{"nctId":1386,"briefTitle":1387,"status":395,"phases":1388,"primaryCompletion":1389,"completion":1390,"start":1391,"enrollment":1392,"conditions":1393,"interventions":1395},"NCT03196791","Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient",[87],"2020-08-09","2020-09-09","2017-10-10",196,[32,1394],"Obesity",[1375],{"trials":1397,"activeCount":96},[],{"trials":1399,"activeCount":96},[],{"intervention":1250,"totalTrials":129,"cells":1401},{"EARLY_PHASE1":1402,"PHASE1":1404,"PHASE2":1406,"PHASE3":1408,"PHASE4":1414,"NA":1416},{"trials":1403,"activeCount":96},[],{"trials":1405,"activeCount":96},[],{"trials":1407,"activeCount":96},[],{"trials":1409,"activeCount":96},[1410],{"nctId":1241,"briefTitle":1242,"status":395,"phases":1411,"primaryCompletion":1244,"completion":1245,"start":1246,"enrollment":1247,"conditions":1412,"interventions":1413},[87],[20],[1230,1250],{"trials":1415,"activeCount":96},[],{"trials":1417,"activeCount":96},[],{"intervention":1419,"totalTrials":129,"cells":1420},"Polyethylene Glycols",{"EARLY_PHASE1":1421,"PHASE1":1423,"PHASE2":1425,"PHASE3":1427,"PHASE4":1439,"NA":1441},{"trials":1422,"activeCount":96},[],{"trials":1424,"activeCount":96},[],{"trials":1426,"activeCount":96},[],{"trials":1428,"activeCount":96},[1429],{"nctId":1430,"briefTitle":1431,"status":395,"phases":1432,"primaryCompletion":799,"completion":1433,"start":1434,"enrollment":1258,"conditions":1435,"interventions":1437},"NCT02980562","Comparison of Low Volume PEG-Asc and Lower Volume PEG-Asc With Bisacodyl",[87],"2015-12","2015-05",[1436,27],"Bowel Disease",[1419,1438],"Bisacodyl",{"trials":1440,"activeCount":96},[],{"trials":1442,"activeCount":96},[],{"intervention":1438,"totalTrials":129,"cells":1444},{"EARLY_PHASE1":1445,"PHASE1":1447,"PHASE2":1449,"PHASE3":1451,"PHASE4":1457,"NA":1459},{"trials":1446,"activeCount":96},[],{"trials":1448,"activeCount":96},[],{"trials":1450,"activeCount":96},[],{"trials":1452,"activeCount":96},[1453],{"nctId":1430,"briefTitle":1431,"status":395,"phases":1454,"primaryCompletion":799,"completion":1433,"start":1434,"enrollment":1258,"conditions":1455,"interventions":1456},[87],[1436,27],[1419,1438],{"trials":1458,"activeCount":96},[],{"trials":1460,"activeCount":96},[],{"intervention":1261,"totalTrials":129,"cells":1462},{"EARLY_PHASE1":1463,"PHASE1":1465,"PHASE2":1467,"PHASE3":1469,"PHASE4":1475,"NA":1477},{"trials":1464,"activeCount":96},[],{"trials":1466,"activeCount":96},[],{"trials":1468,"activeCount":96},[],{"trials":1470,"activeCount":96},[1471],{"nctId":1252,"briefTitle":1253,"status":395,"phases":1472,"primaryCompletion":1255,"completion":1256,"start":1257,"enrollment":1258,"conditions":1473,"interventions":1474},[87],[20,27],[1230,1261],{"trials":1476,"activeCount":96},[],{"trials":1478,"activeCount":96},[],{"intervention":1480,"totalTrials":129,"cells":1481},"gemcitabine, TS-1",{"EARLY_PHASE1":1482,"PHASE1":1484,"PHASE2":1486,"PHASE3":1498,"PHASE4":1500,"NA":1502},{"trials":1483,"activeCount":96},[],{"trials":1485,"activeCount":96},[],{"trials":1487,"activeCount":96},[1488],{"nctId":1489,"briefTitle":1490,"status":395,"phases":1491,"start":1492,"enrollment":1493,"conditions":1494,"interventions":1497},"NCT00436423","A Phase Ⅱ Study of Gemcitabine Combination With TS-1 in Patient With Advanced or Recurred Pancreatic Cancer",[86],"2006-03",38,[1495,1496],"Pancreatic Neoplasm","Neoplasm Metastasis",[1480],{"trials":1499,"activeCount":96},[],{"trials":1501,"activeCount":96},[],{"trials":1503,"activeCount":96},[],{"intervention":1505,"totalTrials":129,"cells":1506},"Oral sotorasib + IV Panitumumab",{"EARLY_PHASE1":1507,"PHASE1":1509,"PHASE2":1511,"PHASE3":1522,"PHASE4":1524,"NA":1526},{"trials":1508,"activeCount":96},[],{"trials":1510,"activeCount":96},[],{"trials":1512,"activeCount":96},[1513],{"nctId":1514,"briefTitle":1515,"status":407,"phases":1516,"primaryCompletion":1517,"completion":542,"start":1518,"enrollment":1519,"conditions":1520,"interventions":1521},"NCT05993455","A Phase 2 Basket Trial in Which Patients With Advanced Solid Tumors Carrying the KRAS G12C mUtation Receive Treatment With a Combination of Sotorasib and Panitumumab",[86],"2023-09-04","2023-07-03",24,[264],[1505],{"trials":1523,"activeCount":96},[],{"trials":1525,"activeCount":96},[],{"trials":1527,"activeCount":96},[],{"intervention":1529,"totalTrials":129,"cells":1530},"Amlodipine10mg",{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1547,"PHASE3":1549,"PHASE4":1551,"NA":1553},{"trials":1532,"activeCount":96},[],{"trials":1534,"activeCount":96},[1535],{"nctId":1536,"briefTitle":1537,"status":395,"phases":1538,"primaryCompletion":1539,"completion":1540,"start":1541,"enrollment":1519,"conditions":1542,"interventions":1544},"NCT03912285","The Pharmacokinetic Interaction Between Amlodipine and Losartan",[85],"2009-03-17","2009-06-09","2008-01-10",[1543],"Healthy",[1529,1545,1546],"Losartan potassium 100mg","Amlodipine plus Losartan",{"trials":1548,"activeCount":96},[],{"trials":1550,"activeCount":96},[],{"trials":1552,"activeCount":96},[],{"trials":1554,"activeCount":96},[],{"intervention":1545,"totalTrials":129,"cells":1556},{"EARLY_PHASE1":1557,"PHASE1":1559,"PHASE2":1565,"PHASE3":1567,"PHASE4":1569,"NA":1571},{"trials":1558,"activeCount":96},[],{"trials":1560,"activeCount":96},[1561],{"nctId":1536,"briefTitle":1537,"status":395,"phases":1562,"primaryCompletion":1539,"completion":1540,"start":1541,"enrollment":1519,"conditions":1563,"interventions":1564},[85],[1543],[1529,1545,1546],{"trials":1566,"activeCount":96},[],{"trials":1568,"activeCount":96},[],{"trials":1570,"activeCount":96},[],{"trials":1572,"activeCount":96},[],{"intervention":1546,"totalTrials":129,"cells":1574},{"EARLY_PHASE1":1575,"PHASE1":1577,"PHASE2":1583,"PHASE3":1585,"PHASE4":1587,"NA":1589},{"trials":1576,"activeCount":96},[],{"trials":1578,"activeCount":96},[1579],{"nctId":1536,"briefTitle":1537,"status":395,"phases":1580,"primaryCompletion":1539,"completion":1540,"start":1541,"enrollment":1519,"conditions":1581,"interventions":1582},[85],[1543],[1529,1545,1546],{"trials":1584,"activeCount":96},[],{"trials":1586,"activeCount":96},[],{"trials":1588,"activeCount":96},[],{"trials":1590,"activeCount":96},[],{"intervention":1592,"totalTrials":129,"cells":1593},"Test-Bepotastine salicylate 9.64 mg",{"EARLY_PHASE1":1594,"PHASE1":1596,"PHASE2":1612,"PHASE3":1614,"PHASE4":1616,"NA":1618},{"trials":1595,"activeCount":96},[],{"trials":1597,"activeCount":96},[1598],{"nctId":1599,"briefTitle":1600,"status":395,"phases":1601,"primaryCompletion":1602,"completion":1603,"start":1604,"enrollment":1605,"conditions":1606,"interventions":1610},"NCT01897428","PK Comparisons of Bepotastine Besilate 10 mg and Bepotastine Salicylate 9.64 mg",[85],"2011-05","2011-08","2011-04",26,[1607,1608,1609],"Allergic Rhinitis","Urticaria","Pruritus",[1592,1611],"Reference-bepotastine besilate 10 mg",{"trials":1613,"activeCount":96},[],{"trials":1615,"activeCount":96},[],{"trials":1617,"activeCount":96},[],{"trials":1619,"activeCount":96},[],{"intervention":1611,"totalTrials":129,"cells":1621},{"EARLY_PHASE1":1622,"PHASE1":1624,"PHASE2":1630,"PHASE3":1632,"PHASE4":1634,"NA":1636},{"trials":1623,"activeCount":96},[],{"trials":1625,"activeCount":96},[1626],{"nctId":1599,"briefTitle":1600,"status":395,"phases":1627,"primaryCompletion":1602,"completion":1603,"start":1604,"enrollment":1605,"conditions":1628,"interventions":1629},[85],[1607,1608,1609],[1592,1611],{"trials":1631,"activeCount":96},[],{"trials":1633,"activeCount":96},[],{"trials":1635,"activeCount":96},[],{"trials":1637,"activeCount":96},[],{"intervention":1639,"totalTrials":129,"cells":1640},"In combination of 0.2mg finasteride and 5mg tamsulosin",{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1655,"PHASE3":1657,"PHASE4":1659,"NA":1661},{"trials":1642,"activeCount":96},[],{"trials":1644,"activeCount":96},[1645],{"nctId":1646,"briefTitle":1647,"status":395,"phases":1648,"primaryCompletion":1649,"completion":1649,"start":1650,"enrollment":1605,"conditions":1651,"interventions":1653},"NCT01829893","PK Comparison of GL2701 With Finasteride and Tamsulosin in Combination",[85],"2012-02","2012-01",[1652],"Benign Prostatic Hyperplasia (BPH)",[1639,1654],"GL2701",{"trials":1656,"activeCount":96},[],{"trials":1658,"activeCount":96},[],{"trials":1660,"activeCount":96},[],{"trials":1662,"activeCount":96},[],{"intervention":1654,"totalTrials":129,"cells":1664},{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1673,"PHASE3":1675,"PHASE4":1677,"NA":1679},{"trials":1666,"activeCount":96},[],{"trials":1668,"activeCount":96},[1669],{"nctId":1646,"briefTitle":1647,"status":395,"phases":1670,"primaryCompletion":1649,"completion":1649,"start":1650,"enrollment":1605,"conditions":1671,"interventions":1672},[85],[1652],[1639,1654],{"trials":1674,"activeCount":96},[],{"trials":1676,"activeCount":96},[],{"trials":1678,"activeCount":96},[],{"trials":1680,"activeCount":96},[],{"intervention":1682,"totalTrials":129,"cells":1683},"FCDP, dapagliflozin 10mg\u002Flinagliptin 5 mg or co-administration of a single dose of dapagliflozin and linagliptin",{"EARLY_PHASE1":1684,"PHASE1":1686,"PHASE2":1697,"PHASE3":1699,"PHASE4":1701,"NA":1703},{"trials":1685,"activeCount":96},[],{"trials":1687,"activeCount":96},[1688],{"nctId":1689,"briefTitle":1690,"status":395,"phases":1691,"primaryCompletion":1692,"completion":1693,"start":1694,"enrollment":476,"conditions":1695,"interventions":1696},"NCT05066516","The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects",[85],"2020-08-18","2020-10-18","2020-06-25",[25],[1682],{"trials":1698,"activeCount":96},[],{"trials":1700,"activeCount":96},[],{"trials":1702,"activeCount":96},[],{"trials":1704,"activeCount":96},[],{"intervention":1706,"totalTrials":129,"cells":1707},"Donepezil, ODT 10 mg",{"EARLY_PHASE1":1708,"PHASE1":1710,"PHASE2":1723,"PHASE3":1725,"PHASE4":1727,"NA":1729},{"trials":1709,"activeCount":96},[],{"trials":1711,"activeCount":96},[1712],{"nctId":1713,"briefTitle":1714,"status":395,"phases":1715,"primaryCompletion":1716,"completion":1717,"start":1196,"enrollment":1718,"conditions":1719,"interventions":1721},"NCT01297036","Pharmacokinetic Comparisons of Two Donepezil Formulations",[85],"2008-03","2008-05",22,[1720],"Alzheimer Disease",[1706,1722],"Donepezil, 10 mg",{"trials":1724,"activeCount":96},[],{"trials":1726,"activeCount":96},[],{"trials":1728,"activeCount":96},[],{"trials":1730,"activeCount":96},[],{"intervention":1722,"totalTrials":129,"cells":1732},{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1741,"PHASE3":1743,"PHASE4":1745,"NA":1747},{"trials":1734,"activeCount":96},[],{"trials":1736,"activeCount":96},[1737],{"nctId":1713,"briefTitle":1714,"status":395,"phases":1738,"primaryCompletion":1716,"completion":1717,"start":1196,"enrollment":1718,"conditions":1739,"interventions":1740},[85],[1720],[1706,1722],{"trials":1742,"activeCount":96},[],{"trials":1744,"activeCount":96},[],{"trials":1746,"activeCount":96},[],{"trials":1748,"activeCount":96},[],{"intervention":1750,"totalTrials":129,"cells":1751},"varenicline tartrate 1mg (HGP1604, R) - varenicline oxalate 1mg (HIP1502, T), RT",{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1766,"PHASE3":1768,"PHASE4":1770,"NA":1772},{"trials":1753,"activeCount":96},[],{"trials":1755,"activeCount":96},[1756],{"nctId":1757,"briefTitle":1758,"status":395,"phases":1759,"primaryCompletion":1760,"completion":1761,"start":1762,"enrollment":185,"conditions":1763,"interventions":1764},"NCT04018378","A Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1502",[85],"2017-05-15","2018-09-17","2017-01-06",[1543],[1750,1765],"varenicline oxalate 1mg (HIP1502, T) - varenicline tartrate 1mg (HGP1604, R), TR",{"trials":1767,"activeCount":96},[],{"trials":1769,"activeCount":96},[],{"trials":1771,"activeCount":96},[],{"trials":1773,"activeCount":96},[],{"intervention":1765,"totalTrials":129,"cells":1775},{"EARLY_PHASE1":1776,"PHASE1":1778,"PHASE2":1784,"PHASE3":1786,"PHASE4":1788,"NA":1790},{"trials":1777,"activeCount":96},[],{"trials":1779,"activeCount":96},[1780],{"nctId":1757,"briefTitle":1758,"status":395,"phases":1781,"primaryCompletion":1760,"completion":1761,"start":1762,"enrollment":185,"conditions":1782,"interventions":1783},[85],[1543],[1750,1765],{"trials":1785,"activeCount":96},[],{"trials":1787,"activeCount":96},[],{"trials":1789,"activeCount":96},[],{"trials":1791,"activeCount":96},[],{"intervention":722,"totalTrials":18,"cells":1793},{"EARLY_PHASE1":1794,"PHASE1":1796,"PHASE2":1798,"PHASE3":1800,"PHASE4":1802,"NA":1826},{"trials":1795,"activeCount":96},[],{"trials":1797,"activeCount":96},[],{"trials":1799,"activeCount":96},[],{"trials":1801,"activeCount":96},[],{"trials":1803,"activeCount":96},[1804,1808,1812,1822],{"nctId":712,"briefTitle":713,"status":407,"phases":1805,"primaryCompletion":715,"completion":588,"start":587,"enrollment":716,"conditions":1806,"interventions":1807},[88],[718],[699,720,721,722,723],{"nctId":840,"briefTitle":841,"status":407,"phases":1809,"primaryCompletion":843,"completion":844,"start":398,"enrollment":845,"conditions":1810,"interventions":1811},[88],[847],[827,849,850,722,851],{"nctId":1813,"briefTitle":1814,"status":407,"phases":1815,"primaryCompletion":843,"completion":844,"start":1816,"enrollment":1199,"conditions":1817,"interventions":1820},"NCT02738814","Propofol for Treatment on Emergence Agitation",[88],"2016-04",[1818,1819],"Child","Anesthesia Morbidity",[1821],"propofol",{"nctId":1168,"briefTitle":1169,"status":407,"phases":1823,"primaryCompletion":1171,"completion":1172,"start":715,"enrollment":1173,"conditions":1824,"interventions":1825},[88],[1175],[722,1155],{"trials":1827,"activeCount":96},[1828],{"nctId":1829,"briefTitle":1830,"status":395,"phases":1831,"primaryCompletion":1832,"completion":1832,"start":1833,"enrollment":1834,"conditions":1835,"interventions":1839},"NCT05407870","Efficacy and Safety of Etomidate Sedation in Gastric Endoscopic Submucosal Dissection",[89],"2022-11-24","2022-06-09",138,[1836,1837,1838],"Sedation Complication","Endoscopic Submucosal Dissection","Esophagogastroduodenoscopy",[1840,722],"Etomidate",{"intervention":1108,"totalTrials":92,"cells":1842},{"EARLY_PHASE1":1843,"PHASE1":1845,"PHASE2":1847,"PHASE3":1849,"PHASE4":1851,"NA":1857},{"trials":1844,"activeCount":96},[],{"trials":1846,"activeCount":96},[],{"trials":1848,"activeCount":96},[],{"trials":1850,"activeCount":96},[],{"trials":1852,"activeCount":96},[1853],{"nctId":1099,"briefTitle":1100,"status":395,"phases":1854,"primaryCompletion":1102,"completion":1102,"start":1103,"enrollment":1104,"conditions":1855,"interventions":1856},[88],[1106],[1108,1086,1109],{"trials":1858,"activeCount":96},[1859],{"nctId":1860,"briefTitle":1861,"status":407,"phases":1862,"primaryCompletion":1863,"completion":1864,"start":1865,"enrollment":1866,"conditions":1867,"interventions":1868},"NCT05328310","Effect of Different Antihypertensive Drugs on Central Blood Pressure",[89],"2022-12","2026-03","2019-01-06",110,[17],[1108],{"intervention":1870,"totalTrials":129,"cells":1871},"Muscle Relaxant",{"EARLY_PHASE1":1872,"PHASE1":1874,"PHASE2":1876,"PHASE3":1878,"PHASE4":1880,"NA":1882},{"trials":1873,"activeCount":96},[],{"trials":1875,"activeCount":96},[],{"trials":1877,"activeCount":96},[],{"trials":1879,"activeCount":96},[],{"trials":1881,"activeCount":96},[],{"trials":1883,"activeCount":96},[1884],{"nctId":1885,"briefTitle":1886,"status":407,"phases":1887,"primaryCompletion":1888,"completion":1888,"start":1889,"enrollment":1890,"conditions":1891,"interventions":1893},"NCT03299621","Monitoring of Anesthetic Depth and EEG Band Power Using PLE (Phase Lag Entropy) During Propofol Anesthesia",[89],"2018-08-31","2017-11-13",35,[1892],"Anesthesia, General",[1870],{"intervention":1895,"totalTrials":129,"cells":1896},"ALDH enzyme supplementation",{"EARLY_PHASE1":1897,"PHASE1":1899,"PHASE2":1901,"PHASE3":1903,"PHASE4":1905,"NA":1907},{"trials":1898,"activeCount":96},[],{"trials":1900,"activeCount":96},[],{"trials":1902,"activeCount":96},[],{"trials":1904,"activeCount":96},[],{"trials":1906,"activeCount":96},[],{"trials":1908,"activeCount":96},[1909],{"nctId":1910,"briefTitle":1911,"status":407,"phases":1912,"primaryCompletion":1913,"completion":1914,"start":1915,"enrollment":1916,"conditions":1917,"interventions":1921},"NCT05030363","ALDH Enzyme in CRF With Advanced GI Cancer",[89],"2022-08-31","2022-12-31","2021-10-25",82,[1918,1919,1920],"Fatigue","Gastrointestinal Cancer","Aldehyde Dehydrogenase",[1895],{"intervention":1923,"totalTrials":129,"cells":1924},"warfarin",{"EARLY_PHASE1":1925,"PHASE1":1927,"PHASE2":1929,"PHASE3":1931,"PHASE4":1933,"NA":1935},{"trials":1926,"activeCount":96},[],{"trials":1928,"activeCount":96},[],{"trials":1930,"activeCount":96},[],{"trials":1932,"activeCount":96},[],{"trials":1934,"activeCount":96},[],{"trials":1936,"activeCount":96},[1937],{"nctId":1938,"briefTitle":1939,"status":407,"phases":1940,"primaryCompletion":398,"completion":1323,"start":1941,"enrollment":1942,"conditions":1943,"interventions":1944},"NCT01991951","Short Term Warfarin Therapy for Radiofrequency Catheter Ablation of Atrial Fibrillation",[89],"2013-07",520,[30],[1923],{"intervention":1946,"totalTrials":129,"cells":1947},"platelet activation factors",{"EARLY_PHASE1":1948,"PHASE1":1950,"PHASE2":1952,"PHASE3":1954,"PHASE4":1956,"NA":1958},{"trials":1949,"activeCount":96},[],{"trials":1951,"activeCount":96},[],{"trials":1953,"activeCount":96},[],{"trials":1955,"activeCount":96},[],{"trials":1957,"activeCount":96},[],{"trials":1959,"activeCount":96},[1960],{"nctId":1961,"briefTitle":1962,"status":407,"phases":1963,"primaryCompletion":1964,"completion":1965,"start":1966,"enrollment":185,"conditions":1967,"interventions":1970},"NCT05165797","Platelet Activation Affecting the Rate of Vascular Access Patency",[],"2021-12-31","2022-07-01","2021-01-01",[1968,1969],"Platelet Activation","Hemodialysis Fistula Thrombosis",[1946],{"intervention":1972,"totalTrials":129,"cells":1973},"Tamoxifen",{"EARLY_PHASE1":1974,"PHASE1":1976,"PHASE2":1978,"PHASE3":1980,"PHASE4":1982,"NA":1984},{"trials":1975,"activeCount":96},[],{"trials":1977,"activeCount":96},[],{"trials":1979,"activeCount":96},[],{"trials":1981,"activeCount":96},[],{"trials":1983,"activeCount":96},[],{"trials":1985,"activeCount":96},[1986],{"nctId":1987,"briefTitle":1988,"status":407,"phases":1989,"primaryCompletion":1816,"completion":1816,"start":1990,"enrollment":1991,"conditions":1992,"interventions":1996},"NCT00973037","CYP2D6 Genotype on the Clinical Effect of Tamoxifen",[],"2009-03",922,[1993,1972,1994,1995],"Breast Neoplasms","Genotype","CYP2D6",[1972],{"intervention":1998,"totalTrials":129,"cells":1999},"Hydromorphone",{"EARLY_PHASE1":2000,"PHASE1":2002,"PHASE2":2004,"PHASE3":2006,"PHASE4":2008,"NA":2010},{"trials":2001,"activeCount":96},[],{"trials":2003,"activeCount":96},[],{"trials":2005,"activeCount":96},[],{"trials":2007,"activeCount":96},[],{"trials":2009,"activeCount":96},[],{"trials":2011,"activeCount":96},[2012],{"nctId":2013,"briefTitle":2014,"status":395,"phases":2015,"primaryCompletion":2016,"completion":2017,"start":2018,"enrollment":927,"conditions":2019,"interventions":2022},"NCT01172782","The Analgesic Effect of Intrathecal Hydromorphone Injection on Spinal Anesthesia",[89],"2010-02","2010-07","2009-07",[2020,2021],"Pain Measurement","Visual Analog Pain Scale",[1998],{"intervention":2024,"totalTrials":129,"cells":2025},"Clopidogrel",{"EARLY_PHASE1":2026,"PHASE1":2028,"PHASE2":2030,"PHASE3":2032,"PHASE4":2034,"NA":2036},{"trials":2027,"activeCount":96},[],{"trials":2029,"activeCount":96},[],{"trials":2031,"activeCount":96},[],{"trials":2033,"activeCount":96},[],{"trials":2035,"activeCount":96},[],{"trials":2037,"activeCount":96},[2038],{"nctId":2039,"briefTitle":2040,"status":395,"phases":2041,"primaryCompletion":2042,"completion":2042,"start":2043,"enrollment":2044,"conditions":2045,"interventions":2048},"NCT02707445","Genotyping Influences Outcome of Coronary Artery Stenting",[89],"2016-02","2011-09",5000,[2046,2047],"Myocardial Ischemia","CLOPIDOGREL, POOR METABOLISM of (Disorder)",[2024],{"intervention":1840,"totalTrials":129,"cells":2050},{"EARLY_PHASE1":2051,"PHASE1":2053,"PHASE2":2055,"PHASE3":2057,"PHASE4":2059,"NA":2061},{"trials":2052,"activeCount":96},[],{"trials":2054,"activeCount":96},[],{"trials":2056,"activeCount":96},[],{"trials":2058,"activeCount":96},[],{"trials":2060,"activeCount":96},[],{"trials":2062,"activeCount":96},[2063],{"nctId":1829,"briefTitle":1830,"status":395,"phases":2064,"primaryCompletion":1832,"completion":1832,"start":1833,"enrollment":1834,"conditions":2065,"interventions":2066},[89],[1836,1837,1838],[1840,722],{"intervention":2068,"totalTrials":129,"cells":2069},"Aromatase Inhibitor",{"EARLY_PHASE1":2070,"PHASE1":2072,"PHASE2":2074,"PHASE3":2076,"PHASE4":2078,"NA":2080},{"trials":2071,"activeCount":96},[],{"trials":2073,"activeCount":96},[],{"trials":2075,"activeCount":96},[],{"trials":2077,"activeCount":96},[],{"trials":2079,"activeCount":96},[],{"trials":2081,"activeCount":96},[2082],{"nctId":2083,"briefTitle":2084,"status":407,"phases":2085,"primaryCompletion":2086,"completion":2086,"start":1990,"enrollment":1199,"conditions":2087,"interventions":2091},"NCT00973505","CYP19 Genetic Polymorphism & Aromatase Inhibitor(AI)",[],"2010-09",[1993,2088,2089,2090],"Arthralgia","Arthritis","Genetic Polymorphism",[2068],{"intervention":2093,"totalTrials":129,"cells":2094},"Midazolam 0.03mg\u002Fkg",{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2099,"PHASE3":2101,"PHASE4":2103,"NA":2105},{"trials":2096,"activeCount":96},[],{"trials":2098,"activeCount":96},[],{"trials":2100,"activeCount":96},[],{"trials":2102,"activeCount":96},[],{"trials":2104,"activeCount":96},[],{"trials":2106,"activeCount":96},[2107],{"nctId":2108,"briefTitle":2109,"status":395,"phases":2110,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":2111,"conditions":2112,"interventions":2114},"NCT01680471","A Study on the Effects of Midazolam on Delirium After Sevoflurane Anesthesia in Pediatric Strabismus Surgery",[89],90,[1818,1819,2113],"Delirium on Emergence",[2093,2115],"Midazolam 0.05mg\u002Fkg",{"intervention":2115,"totalTrials":129,"cells":2117},{"EARLY_PHASE1":2118,"PHASE1":2120,"PHASE2":2122,"PHASE3":2124,"PHASE4":2126,"NA":2128},{"trials":2119,"activeCount":96},[],{"trials":2121,"activeCount":96},[],{"trials":2123,"activeCount":96},[],{"trials":2125,"activeCount":96},[],{"trials":2127,"activeCount":96},[],{"trials":2129,"activeCount":96},[2130],{"nctId":2108,"briefTitle":2109,"status":395,"phases":2131,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":2111,"conditions":2132,"interventions":2133},[89],[1818,1819,2113],[2093,2115],{"intervention":2135,"totalTrials":129,"cells":2136},"clopidogrel 75mg",{"EARLY_PHASE1":2137,"PHASE1":2139,"PHASE2":2141,"PHASE3":2143,"PHASE4":2145,"NA":2147},{"trials":2138,"activeCount":96},[],{"trials":2140,"activeCount":96},[],{"trials":2142,"activeCount":96},[],{"trials":2144,"activeCount":96},[],{"trials":2146,"activeCount":96},[],{"trials":2148,"activeCount":96},[2149],{"nctId":2150,"briefTitle":2151,"status":395,"phases":2152,"primaryCompletion":2153,"completion":2154,"start":2155,"enrollment":2156,"conditions":2157,"interventions":2159},"NCT03759067","Method of Clopidogrel Pre-treatment Undergoing Conventional Coronary Angiogram in Angina Patients",[89],"2012-01-31","2013-07-31","2010-10-18",511,[2158],"Angina, Stable",[2135,2160,2161],"Clopidogrel 300 mg","clopidogrel 600mg",{"intervention":2160,"totalTrials":129,"cells":2163},{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2168,"PHASE3":2170,"PHASE4":2172,"NA":2174},{"trials":2165,"activeCount":96},[],{"trials":2167,"activeCount":96},[],{"trials":2169,"activeCount":96},[],{"trials":2171,"activeCount":96},[],{"trials":2173,"activeCount":96},[],{"trials":2175,"activeCount":96},[2176],{"nctId":2150,"briefTitle":2151,"status":395,"phases":2177,"primaryCompletion":2153,"completion":2154,"start":2155,"enrollment":2156,"conditions":2178,"interventions":2179},[89],[2158],[2135,2160,2161],{"intervention":2161,"totalTrials":129,"cells":2181},{"EARLY_PHASE1":2182,"PHASE1":2184,"PHASE2":2186,"PHASE3":2188,"PHASE4":2190,"NA":2192},{"trials":2183,"activeCount":96},[],{"trials":2185,"activeCount":96},[],{"trials":2187,"activeCount":96},[],{"trials":2189,"activeCount":96},[],{"trials":2191,"activeCount":96},[],{"trials":2193,"activeCount":96},[2194],{"nctId":2150,"briefTitle":2151,"status":395,"phases":2195,"primaryCompletion":2153,"completion":2154,"start":2155,"enrollment":2156,"conditions":2196,"interventions":2197},[89],[2158],[2135,2160,2161]]